Labcorp Expands PathAI Agreement to Deploy Digital Pathology Platform Across U.S. Network

The agreement supports the rollout of PathAI’s AISight Dx software to enable digital case management, slide review, collaboration, and annotation workflows.

Labcorp has expanded its collaboration with PathAI to deploy a digital pathology platform across its anatomic pathology laboratories and hospital sites in the United States. The agreement supports the rollout of PathAI’s AISight Dx software to enable digital case management, slide review, collaboration, and annotation workflows.

Under the expanded pact, Labcorp’s pathologists will use AISight Dx to review, interpret, and manage digital images of scanned surgical pathology slides for primary diagnosis. The software supports AI-powered image analysis, secure storage, and system connectivity designed to streamline operations and improve workflow efficiency.

PathAI’s digital pathology platform received clearance from the U.S. Food and Drug Administration in 2022. In 2025, the company secured additional 510(k) clearance, allowing it to validate and implement specified major changes — including additional displays, scanners, file formats, and browsers — without submitting new premarket notifications.

Labcorp first invested in PathAI in 2019 and expanded its use of the company’s technology in 2021 to support clinical trials. At the time of the initial investment, PathAI said the collaboration would support the eventual integration of its artificial intelligence-enabled computational pathology tools into clinical laboratories. The latest expansion marks a broader deployment of the AISight Dx platform across Labcorp’s U.S. network.

Marcia Eisenberg, chief scientific officer at Labcorp, said in a statement that the expanded agreement will enable the company to scale digital pathology nationwide and integrate AI-driven insights into routine clinical care. The company is pursuing faster and more consistent diagnostic processes through digital transformation of pathology workflows.

Labcorp’s broader AI strategy extends beyond digital slide management. Speaking at the J.P. Morgan Healthcare Conference in January, CEO Adam Schechter said the company is exploring AI applications across laboratory, microbiology, cytology, and pathology operations. He stated that AI tools could help pathologists identify areas of concern more quickly and enable virtual staining of tissue samples to support multiple forms of analysis.

Labcorp’s main competitor, Quest Diagnostics, licensed AISight Dx in 2024 alongside its $100 million acquisition of PathAI’s diagnostic laboratory in Memphis, Tennessee.

Stay tuned for more such updates on Digital Health News